Dr. Chitra Hosing, MD

Dr. Hosing practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Hosing's NPI, 1245322262, was assigned on September 28, 2006. Dr. Hosing graduated from Lady Hardinge Medical College in 1985. Dr. Hosing holds Texas license K8216.

Dr. Hosing's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Hosing's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hosing practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Hosing's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Hosing is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Hosing's licenses on file in 10 states: Texas, Florida, Georgia, Tennessee, Oklahoma, Washington, Alabama, Arizona, Louisiana and Mississippi.

Dmand AI lists anemia, chronic leukemia, lymphoma, multiple myeloma, neutropenia and purpura and thrombocytopenia among the conditions Dr. Hosing treats.

CMS data shows 564 Medicare services from Dr. Hosing across 5 procedure codes in 2024, for 202 Medicare patients. Medicare paid $45,815 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 202 Medicare patients who saw Dr. Hosing in 2024. The largest group is 65 to 74, with 137 patients. 75% of them have high blood pressure, and 70% have high cholesterol. Their average risk score is 2.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hosing's median patient age at 67, with 43% women.

In 2024, Dr. Hosing wrote 142 Medicare Part D claims for 32 patients. 87% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $601 in total drug cost. In 2023, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Hosing for performance year 2024, reported as part of a group. Dr. Hosing accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hosing as offering telehealth.

Dmand AI links 323 papers to Dr. Hosing, published from 2003 to 2025. 2016 was the busiest year, with 28. The most frequent topics are Hematopoietic Stem Cell Transplantation, Transplantation Conditioning and Graft vs Host Disease. Dr. Hosing has published most often in Biol Blood Marrow Transplant. Dr. Hosing's most frequent co-authors are Richard E. Champlin, MD, Uday R. Popat, MD and Elizabeth J. Shpall, MD.

Dmand AI links Dr. Hosing to 16 clinical trials, 5 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin and Multiple Myeloma. M.D. Anderson Cancer Center sponsors the most, 13.

CMS Open Payments shows 25 general payments to Dr. Hosing from 6 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 81% of the total. Sanofi and Genzyme US Companies paid the most, $8,760.

Dr. Hosing graduated from Lady Hardinge Medical College in 1985.

Dr. Hosing is in network with 15 carriers, including Aetna, Elevance and United Healthcare. HMO plans come from the most carriers, 9. Check the plan with the practice before a visit.